PacBio JPM 2026 Presentation.pdf

1、1J.P.Morgan Healthcare ConferenceJanuary 12,2026Christian Henry,President and CEO2Forward-looking statementsAll statements in this presentation(and any accompanying oral presentation)that are not historical of fact are“forward-looking statements”within the meaning of Section 21E of the Securities Ex

2、change Act of 1934,as amended,and the U.S.Private Securities Litigation Reform Act of 1995,includingstatements relating to our preliminary financial results as of and for the quarterand year ended December 31,2025 as well as our expectations for future operating results,revenue,revenue mix,margins,g

3、uidance,goals and operating plans;expectationswith respect to the commercial success of theRevioand Vega systems;expectations with respect to development and commercialization timeframes;future availability,uses,accuracy,sensitivity,advantages,compatibility,pricing,specifications,quality or performa

4、nce of,or benefits or expected benefits ofusing,PacBio products or technologies,including theRevio and Vega systems;throughput,scalability,affordability,coverage,run times,data,density,type and cost per genome,pricing,consumable requirements,numberof genomes that can be sequenced per year;and relate

5、d improvements in yield and accuracy;schedule flexibility and downtime;references that PacBio iscreating the worlds most advanced sequencing technologies;expected results and delivery timeframes;expectations regarding competition in the short-andlong-read sequencing technologies markets;expectations

6、 regarding lowering the cost of long-read sequencing through SPRQ-Nx chemistry and the launch of SPRQ-Nx;expectations regarding the positioning of HiFi technology;expectations regarding the expansion of programs,utilization,and adoption;references that PacBios industry-leading comprehensive datasets